Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)
Year: 2016
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Andrew A. Lane, Kendra L. Sweet, Eunice S. Wang, William B. Donnellan, Roland B. Walter, Anthony S. Stein, David A Rizzieri, Hetty E. Carraway, Ioannis Mantzaris, Thomas Prebet, Michael B. Maris, Stefan Faderl, Dale L. Bixby, Janice Chen, Ross Lindsay, Shay Shemesh, Christopher L. Brooks, Richard M. Stone, Hagop M. Kantarjian, Elias J. Jabbour, Marina Konopleva
Institutions: Dana-Farber Cancer Institute, Moffitt Cancer Center, Roswell Park Comprehensive Cancer Center, Sarah Cannon, Fred Hutch Cancer Center, City Of Hope National Medical Center, City of Hope, Duke Medical Center, Cleveland Clinic, Albert Einstein College of Medicine, Montefiore Medical Center, Yale University, Colorado Blood Cancer Institute, Hackensack University Medical Center, University of Michigan, Michigan Medicine, Stemline Therapeutics (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2782108932